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Clinical
Communications: Adult
AORTIC ARCH THROMBUS AND PULMONARY EMBOLISM IN A COVID-19 PATIENT
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, Abstract—Background: Coronavirus disease 2019
(COVID-19) is associated with endothelial inflammation
and a hypercoagulable state resulting in both venous and
arterial thromboembolic complications. We present a case
of COVID-19-associated aortic thrombus in an otherwise
healthy patient. Case Report: A 53-year-old woman with
no past medical history presented with a 10-day history of
dyspnea, fever, and cough. Her pulse oximetry on room air
was 84%. She tested positive for severe acute respiratory
syndrome coronavirus 2 infection, and chest radiography
revealed moderate patchy bilateral airspace opacities.
Serology markers for cytokine storm were significantly
elevated, with a serum D-dimer level of 8180 ng/mL
(normal < 230 ng/mL). Computed tomography of the chest
with i.v. contrast was positive for bilateral ground-glass
opacities, scattered filling defects within the bilateral
segmental and subsegmental pulmonary arteries, and a
large thrombus was present at the aortic arch. The patient
was admitted to the intensive care unit and successfully
treated with unfractionated heparin, alteplase 50 mg, and
argatroban 2 mg/kg/min. Why Should an Emergency Physician Be Aware of This?: Mural aortic thrombus is a rare but
serious cause of distal embolism and is typically discovered
during an evaluation of cryptogenic arterial embolization to
the viscera or extremities. Patients with suspected hypercoagulable states, such as that encountered with COVID-19,
should be screened for thromboembolism, and when identified, aggressively anticoagulated. Ó 2020 Elsevier Inc. All
rights reserved.
, Keywords—COVID-19; aortic thrombus;
thromboembolism; hypercoagulable state

INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic has
affected more than 20 million humans globally and
caused over 164,000 deaths in the United States alone.
Up to 20% of all COVID-19 patients require hospitalization, and 10% may develop severe symptoms that will
require admission to an intensive care unit and mechanical ventilation (1). From initial reports, it has become
clear that a large percentage of these critically ill patients
develop a prothrombotic state that has been attributed to a
variety of factors, including antiphospholipid antibodies
and vascular endothelial inflammation (endotheliitis)
(2,3). We report the case of a patient who presented to
our institution with severe acute respiratory syndrome
due to COVID-19, complicated by a large-vessel thrombosis.
CASE REPORT
An otherwise healthy 53-year-old woman presented with
dyspnea, fever, and cough that had started approximately
10 days prior to her hospitalization. The patient tested
positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In the Emergency Department she was noted to be afebrile but hypoxic. Oxygen
saturation was 84% on room air, improving to 88%
with a nasal cannula and to 98% with a nonrebreather
mask. Initial blood tests showed a serum D-dimer level
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of 8180 ng/mL (normal < 230 ng/mL), activated partial
thromboplastin time 33.5 s (normal 27.5–35.5 s), prothrombin time 12.2 s (normal 10.6–13.6 s), international
normalized ratio 1.08 (normal 0.88–1.16 ratio), and
platelet count 281  109/L (normal 150–400 K/uL).
Serum ferritin level peaked at 1058 ng/mL (normal, 15–
150 ng/mL) and C-reactive protein at 10.04 mg/dL
(normal < 0.4 mg/dL). Chest x-ray study revealed moderate patchy bilateral airspace opacities, worse in the mid to
lower lungs. Computed tomography examination of the
chest revealed severe bilateral ground-glass opacities in
the lungs with some subpleural sparing and a more consolidative appearance at the bilateral lower lobes
(Figures 1A and 1B). There was no pleural effusion.
There were scattered filling defects within the bilateral
segmental and subsegmental pulmonary arteries, with a
mild to moderate clot burden. The heart was within
normal limits in size, with no evidence of right heart
strain. A large thrombus was present at the aortic arch
(Figures 2A and 2B). The ascending and descending aorta
were not enlarged, with no evidence of atherosclerosis or
vessel wall abnormality. The aortic arch had atherosclerotic plaque at the site of thrombus without evidence of
penetrating ulcer. There were no signs of central nervous
system, hepatic, renal, splenic, or peripheral embolization. A thrombus was also seen in the suprahepatic inferior vena cava (Figure 2C). Venous duplex of the lower
extremities did not reveal any evidence of deep venous
thrombosis. The patient was treated with hydroxychloroquine 400 mg/day, azithromycin 250 mg/day, unfractionated heparin, alteplase 50 mg, and argatroban 2 mg/kg/
min, with partial resolution of the thrombus on followup computed tomography and no in-hospital adverse
events.
DISCUSSION
COVID-19 has a broad range of clinical manifestations.
Although initially described as a respiratory disease

resulting in severe and progressive respiratory failure, a
disproportionate number of patients have developed cardiovascular involvement across different organs and multiple vascular beds. Case reports and observational cohort
studies support both a hypercoagulable state and a
thrombo-inflammatory response associated with SARSCoV-2 infection. Blood coagulation derangements
including elevated D-dimer, fibrinogen, and fibrin degradation products, as well as low antithrombin levels
compared with a healthy control population, are documented (4). D-dimer elevations more than 1000 ng/mL
have been associated with increased COVID-19 mortality
(5). Although there are no set cut-off values for the workup of active thromboembolic disease in patients with
COVID-19, a single-center retrospective study suggested
that a D-dimer cutoff of > 3000 ng/mL predicted venous
thromboembolism with a sensitivity, specificity, and
negative predictive value of 76.9%, 94.9%, and 92.5%,
respectively (6).
The incidence of venous thromboembolism during
COVID-19 infection is reported as high as 25%, and arterial vascular events in up to 4% (7,8). Kashi et al. reported
seven cases of severe arterial thrombosis, including two
COVID-19 patients with asymptomatic floating thoracic
aortic thrombi (9). Hypercoagulable states are commonly
identified in patients with aortic mural thrombus (10).
There are numerous therapeutic options for the management of aortic mural thrombus. However, no definitive
consensus on treatment of aortic thrombus exists. Fayad
et al. found that patients receiving anticoagulation, either
as the primary treatment modality or after aortic surgery,
were less likely to experience recurrent peripheral
embolic events (odds ratio 0.3; 95% confidence interval
0.1–1) (10). An anticoagulation first approach is recommended in the setting of mild distal organ involvement
(11).
Pharmacological thrombosis prophylaxis and treatment in all COVID-19 patients have been empiric and
vary across institutions. Until further data are available,

Figure 1. Chest computed tomography with (A) sagittal and (B) coronal views showing ground-glass opacities (arrows).
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Figure 2. (A) Computed tomography (CT) with three-dimensional reconstruction of the aortic arch with a filling defect (arrow). (B)
Coronal view of the chest, with a large thrombus present in the aortic arch (arrow). (C) CT of the chest with a thrombus seen in the
suprahepatic portion of the inferior vena cava (arrow).

COVID-19 patients with embolic complications should
be screened and aggressively treated for possible largevessel thrombosis.
WHY SHOULD AN EMERGENCY PHYSICIAN BE
AWARE OF THIS?
Mural aortic thrombus is a rare but serious cause of distal
embolism, and is typically discovered during an evaluation of cryptogenic arterial embolization to the viscera
or extremities. Patients with suspected hypercoagulable
states, such as that encountered with COVID-19, should
be aggressively anticoagulated and referred to endovascular services.
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